Vaxcyte, Inc. PCVX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $958.95M+20.7% | $794.31M+15.8% | $685.86M+15.7% | $592.86M+11.8% | $530.19M+11.2% | ||
| $129.78M+0.3% | $129.37M+2.9% | $125.7M+8.1% | $116.24M+10.0% | $105.68M+13.7% | ||
| $1.09B+17.9% | $923.68M+13.8% | $811.56M+14.4% | $709.11M+11.5% | $635.87M+11.6% | ||
| -$1.09B-17.9% | -$923.68M-13.8% | -$811.56M-14.4% | -$709.11M-11.5% | -$635.87M-11.6% | ||
| $142.2M-9.5% | $157.05M+1.7% | $154.36M-4.5% | $161.61M+28.0% | $126.24M+19.5% | ||
| -$946.53M-23.5% | -$766.63M-16.7% | -$657.2M-20.0% | -$547.5M-7.4% | -$509.63M-9.9% | ||
| -$6.88-22.4% | -$5.62-16.1% | -$4.84-17.8% | -$4.11-3.0% | -$3.99-5.0% | ||
| -$1.07B-18.2% | -$907.28M-13.4% | -$799.8M-14.5% | -$698.62M-11.4% | -$626.91M-11.4% | ||
| -$1.09B-17.9% | -$923.68M-13.8% | -$811.56M-14.4% | -$709.11M-11.5% | -$635.87M-11.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Vaxcyte, Inc. profitable?
- Vaxcyte, Inc. is not currently profitable: it reported a net loss of $946.5M over the trailing twelve months.
- What is Vaxcyte, Inc.'s earnings per share?
- Vaxcyte, Inc.'s diluted EPS over the trailing twelve months is $-6.88.
- Where does Vaxcyte, Inc.'s income statement data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.